Key Points Corbus Pharmaceuticals has surged over 300% year-to-date after releasing promising data on January 26 from its Phase 1 trial on CRB-701. Oppenheimer's target raise to $51, alongside a significant insider purchase, signals optimism for Corbus Pharmaceuticals. Recent insider purchasing of over$9 million indicates strong confidence in Corbus Pharmaceuticals' future. 5 stocks we like better than Corbus Pharmaceuticals Shares of Corbus Pharmaceuticals NASDAQ: CRBP have already experienced a meteoric ...